Literature DB >> 18344805

Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.

April Bingham1, Gulnara Mamyrova, Kristina I Rother, Elif Oral, Elaine Cochran, Ahalya Premkumar, David Kleiner, Laura James-Newton, Ira N Targoff, Janardan P Pandey, Danielle Mercatante Carrick, Nancy Sebring, Terrance P O'Hanlon, Maria Ruiz-Hidalgo, Maria Turner, Leslie B Gordon, Jorge Laborda, Steven R Bauer, Perry J Blackshear, Lisa Imundo, Frederick W Miller, Lisa G Rider.   

Abstract

We describe the clinical features of 28 patients with juvenile dermatomyositis (JDM) and 1 patient with adult-onset dermatomyositis (DM), all of whom developed lipodystrophy (LD) that could be categorized into 1 of 3 phenotypes, generalized, partial, or focal, based on the pattern of fat loss distribution. LD onset was often delayed, beginning a median of 4.6 years after diagnosis of DM. Calcinosis, muscle atrophy, joint contractures, and facial rash were DM disease features found to be associated with LD. Panniculitis was associated with focal lipoatrophy while the anti-p155 autoantibody, a newly described myositis-associated autoantibody, was more associated with generalized LD. Specific LD features such as acanthosis nigricans, hirsutism, fat redistribution, and steatosis/nonalcoholic steatohepatitis were frequent in patients with LD, in a gradient of frequency and severity among the 3 sub-phenotypes. Metabolic studies frequently revealed insulin resistance and hypertriglyceridemia in patients with generalized and partial LD. Regional fat loss from the thighs, with relative sparing of fat loss from the medial thighs, was more frequent in generalized than in partial LD and absent from DM patients without LD. Cytokine polymorphisms, the C3 nephritic factor, insulin receptor antibodies, and lamin mutations did not appear to play a pathogenic role in the development of LD in our patients. LD is an under-recognized sequela of JDM, and certain DM patients with a severe, prolonged clinical course and a high frequency of calcinosis appear to be at greater risk for the development of this complication. High-risk JDM patients should be screened for metabolic abnormalities, which are common in generalized and partial LD and result in much of the LD-associated morbidity. Further study is warranted to investigate the pathogenesis of acquired LD in patients with DM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18344805      PMCID: PMC2674585          DOI: 10.1097/MD.0b013e31816bc604

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  59 in total

1.  Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients.

Authors:  F Formiga; J F Meco; X Pinto; J Jacob; I Moga; R Pujol
Journal:  Lupus       Date:  2001       Impact factor: 2.911

2.  The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr.

Authors:  L J McCann; A D Juggins; S M Maillard; L R Wedderburn; J E Davidson; K J Murray; C A Pilkington
Journal:  Rheumatology (Oxford)       Date:  2006-03-27       Impact factor: 7.580

3.  Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

Authors:  E Arioglu; J Duncan-Morin; N Sebring; K I Rother; N Gottlieb; J Lieberman; D Herion; D E Kleiner; J Reynolds; A Premkumar; A E Sumner; J Hoofnagle; M L Reitman; S I Taylor
Journal:  Ann Intern Med       Date:  2000-08-15       Impact factor: 25.391

4.  Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.

Authors:  A M Huber; B Lang; C M LeBlanc; N Birdi; R K Bolaria; P Malleson; I MacNeil; J A Momy; G Avery; B M Feldman
Journal:  Arthritis Rheum       Date:  2000-03

5.  Childhood acquired lipodystrophy: a retrospective study.

Authors:  Elena Pope; Allison Janson; Amina Khambalia; Brian Feldman
Journal:  J Am Acad Dermatol       Date:  2006-06-13       Impact factor: 11.527

6.  Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia.

Authors:  Vinaya Simha; Abhimanyu Garg
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

7.  A novel autoantibody to a 155-kd protein is associated with dermatomyositis.

Authors:  Ira N Targoff; Gulnara Mamyrova; Edward P Trieu; Osvaldo Perurena; Bhanu Koneru; Terrance P O'Hanlon; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2006-11

8.  Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies: I. Physician, parent, and patient global assessments. Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors:  L G Rider; B M Feldman; M D Perez; R M Rennebohm; C B Lindsley; L S Zemel; C A Wallace; S H Ballinger; S L Bowyer; A M Reed; M H Passo; I M Katona; F W Miller; P A Lachenbruch
Journal:  Arthritis Rheum       Date:  1997-11

9.  Genetic variations in ZFP36 and their possible relationship to autoimmune diseases.

Authors:  Danielle Mercatante Carrick; Patricia Chulada; Rachelle Donn; Martina Fabris; Janet McNicholl; William Whitworth; Perry J Blackshear
Journal:  J Autoimmun       Date:  2006-03-20       Impact factor: 7.094

10.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

Authors:  Kittichai Promrat; Glen Lutchman; Gabriel I Uwaifo; Renee J Freedman; Alejandro Soza; Theo Heller; Edward Doo; Marc Ghany; Ahalya Premkumar; Yoon Park; T Jake Liang; Jack A Yanovski; David E Kleiner; Jay H Hoofnagle
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

View more
  45 in total

1.  Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

Authors:  G Esther A Habers; Adam M Huber; Gulnara Mamyrova; Ira N Targoff; Terrance P O'Hanlon; Sharon Adams; Janardan P Pandey; Chantal Boonacker; Marco van Brussel; Frederick W Miller; Annet van Royen-Kerkhof; Lisa G Rider
Journal:  Arthritis Rheumatol       Date:  2016-03       Impact factor: 10.995

Review 2.  Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors:  Lisa G Rider; James D Katz; Olcay Y Jones
Journal:  Rheum Dis Clin North Am       Date:  2013-09-19       Impact factor: 2.670

Review 3.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

4.  Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis.

Authors:  Micah J Eimer; Wendy J Brickman; Roopa Seshadri; Rosalind Ramsey-Goldman; David D McPherson; Beverly Smulevitz; Neil J Stone; Lauren M Pachman
Journal:  J Pediatr       Date:  2011-07-23       Impact factor: 4.406

5.  Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126.

Authors:  Erin Kim; Joan Cook-Mills; Gabrielle Morgan; Simone T Sredni; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2012-11

6.  Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis.

Authors:  Takayuki Kishi; William Warren-Hicks; Nastaran Bayat; Ira N Targoff; Adam M Huber; Michael M Ward; Lisa G Rider
Journal:  Rheumatology (Oxford)       Date:  2021-05-14       Impact factor: 7.580

7.  A Report of Three Cases With Acquired Generalized Lipodystrophy With Distinct Autoimmune Conditions Treated With Metreleptin.

Authors:  Jasmin Lebastchi; Nevin Ajluni; Adam Neidert; Elif A Oral
Journal:  J Clin Endocrinol Metab       Date:  2015-09-21       Impact factor: 5.958

Review 8.  Advances in Juvenile Dermatomyositis: Myositis Specific Antibodies Aid in Understanding Disease Heterogeneity.

Authors:  Lauren M Pachman; Amer M Khojah
Journal:  J Pediatr       Date:  2018-04       Impact factor: 4.406

Review 9.  Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.

Authors:  Yoshinao Muro; Kazumitsu Sugiura; Masashi Akiyama
Journal:  Clin Rev Allergy Immunol       Date:  2016-12       Impact factor: 8.667

Review 10.  The evolving spectrum of polymyositis and dermatomyositis--moving towards clinicoserological syndromes: a critical review.

Authors:  Sarah Tansley; Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.